Grifols
RESEARCH TRIANGLE PARK, North Carolina, June 6, 2011 -
- Following the recent acquisition of Talecris Biotherapeutics, Grifols
has established a new Board of Directors for its US operations that draws on
some of industry's most well-known and experienced leaders, who will assure a
smooth integration of the two companies and create a new leader in the plasma
therapies market.
BARCELONA, Spain, March 7, 2011 - Grifols, a global healthcare company and biopharmaceutical manufacturer
based in Barcelona, Spain today announced that it has established an Expert
Advisory Council in Transfusion Medicine drawing on the expertise of
internationally renowned physicians and researchers from across the globe.
LOS ANGELES, November 22, 2010 - Grifols today announced availability of its recently approved
Flebogamma(R) 10% DIF intravenous immune globulin.
